ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0395

Assessment of Enthesitis by Pediatric Rheumatology Providers

Erin Treemarcki1, Shirley Tse2, Marisa Klein-Gitelman3, Adam Mayer4, Hemalatha Srinivasalu5, Heather Walters6 and Melissa Oliver7, and the CARRA Juvenile Spondyloarthritis Workgroup and the CARRA investigators, 1University of Utah, Salt Lake City, UT, 2SickKids, Toronto, ON, Canada, 3Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 5Children's National Hospital, Washington, DC, 6Northwell Health, New Hyde Park, NY, 7Indiana University, Indianapolis, IN

Meeting: ACR Convergence 2024

Keywords: Juvenile idiopathic arthritis, Pediatric rheumatology, spondyloarthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Enthesitis is a characteristic feature of enthesitis related arthritis (ERA) but can be found in other juvenile idiopathic arthritis (JIA) subtypes. It occurs with greater frequency in juvenile ERA than in adult-onset ankylosing spondylitis.  Enthesitis indices exist for adults with spondyloarthritis, but there is no such measure for pediatric patients. This introduces the potential for variability in assessing for enthesitis and diagnosing enthesitis. We aimed to determine the frequency of and indications for assessing enthesitis in clinical practice in addition to the sites most assessed and what factors contribute to the diagnosis of enthesitis.

Methods: A survey was developed and refined by members of the CARRA Juvenile Spondyloarthritis (JSpA) Workgroup. The survey was then further refined using input from experts at the CARRA JIA Forum and through pilot testing. Survey questions included demographics, practice patterns around assessment of enthesitis, and knowledge of enthesitis. The survey was distributed electronically to CARRA members with reminders sent every 2 weeks over a 2-month period. Responses were analyzed using descriptive statistics.

Results: Of the 343 who opened the survey, 139 responded (40.5% response rate).  Respondents were predominantly pediatric rheumatologists (76.3%) at academic medical centers (91.1%) in the US (86.0%) (Table 1). Providers were asked in which scenarios they routinely assess enthesitis, and the top answers were patients with ERA (92.6%); patients with HLA B27 associated conditions such as uveitis, psoriasis and inflammatory bowel disease (86.8%); JPsA (85.1%); new patients with concern for JIA (80.1%); and undifferentiated JIA (76.0%). Only 4% of respondents use an established enthesitis scoring measure, but most are interested in a scoring tool being created for pediatric patients (83.3%). The most assessed sites for enthesitis were in the lower extremities with the Achilles tendon being assessed by all respondents (Figure 1). Reported features most concerning for enthesitis were tenderness (100%), swelling (81.7%), and pain with motion/heel walk/squatting (73.9%).

Conclusion: Most providers are interested in a pediatric-specific enthesitis scoring system. There are similarities in current practice patterns in clinical enthesitis evaluation with a higher likelihood of checking for enthesitis in certain JIA subtypes with entheseal sites in the lower extremities most commonly evaluated. Future steps include development of a pediatric enthesitis scoring tool that would standardize enthesitis evaluation and could be used as both a clinical and research tool.

Supporting image 1

Table 1. Respondent demographics.

Supporting image 2

Table 2. Assessment of enthesitis in clinical practice.

Supporting image 3

Figure 1: Entheses routinely assessed on exam by respondents.


Disclosures: E. Treemarcki: None; S. Tse: None; M. Klein-Gitelman: AbbVie/Abbott, 2, AstraZeneca, 2, Eli Lilly, 1; A. Mayer: None; H. Srinivasalu: None; H. Walters: None; M. Oliver: None.

To cite this abstract in AMA style:

Treemarcki E, Tse S, Klein-Gitelman M, Mayer A, Srinivasalu H, Walters H, Oliver M. Assessment of Enthesitis by Pediatric Rheumatology Providers [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/assessment-of-enthesitis-by-pediatric-rheumatology-providers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-enthesitis-by-pediatric-rheumatology-providers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology